Search

Your search keyword '"Mancuso, M. E."' showing total 2 results
Start Over Author "Mancuso, M. E." Publisher blackwell publishing ltd
2 results on '"Mancuso, M. E."'

1. Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET

Author

Coppola, A., Castaman, G., Santoro, R. C., Mancuso, M. E., Franchini, M., Marino, R., Rivolta, G. F., Santoro, C., Zanon, E., Sciacovelli, L., Manca, S., Lubrano, R., Golato, M., Tripodi, A., Rocino, A., Bernardini, S., Biasoli, C., Borchiellini, A., Cultrera, D., De Cristofaro, R., Di Minno, G., Gamba, G., Giampaolo, A., Giuffrida, A. C., Giuffrida, C., Gresele, P., Mazzucconi, M. G., Morfini, M., Hassan, H. J., Molinari, A. C., Pollio, B., Sargentini, V., Tagliaferri, A., Tosetto, A., and Zampogna, S.

Subjects
FVIII, Laboratory monitoring, Haemophilia A, haemophilia A, 030204 cardiovascular system & hematology, Antibodies, Monoclonal, Humanized, Hemophilia A, Haemophilia, surgery, 03 medical and health sciences, 0302 clinical medicine, Antibodies, Bispecific, Health care, medicine, bleeding, emergency, emicizumab, Humans, In patient, Genetics (clinical), Emicizumab, Emergency management, business.industry, Hematology, General Medicine, medicine.disease, Severe haemophilia A, Medical emergency, business, 030215 immunology
Abstract

Introduction The factor VIII (FVIII)-mimetic bispecific monoclonal antibody, emicizumab, previously approved for prophylaxis in haemophilia A with inhibitors, has been recently licensed in several countries also in patients with severe haemophilia A (PWSHA) without inhibitors. The introduction of this innovative agent requires the development of specific pathways at Haemophilia Treatment Centres (HTC), particularly regarding laboratory testing and treatment of breakthrough bleeds and invasive procedures/surgeries, even more critical when patients are managed by non-specialist professionals. Limited literature data and clinical experience in PWSHA without inhibitors on emicizumab are currently available. Aim To promote awareness and overcome these challenges, the Italian Association of Haemophilia Centres (AICE) issued a guidance on the management of PWSHA without inhibitors on emicizumab prophylaxis, focused on emergency and shared with other National Scientific Societies in the field. Methods The document, drafted by an AICE expert panel and approved through online consultation, was further revised by a multidisciplinary working group, including members of 5 haemostasis, laboratory and emergency scientific societies. The final version was approved by the Council of each society. Results General recommendations about use of FVIII concentrates for the treatment of bleeding or haemostatic coverage of invasive procedures/surgeries and laboratory monitoring in PWSHA without inhibitors on emicizumab are provided. Specific issues of the management in the emergency room are focused, highlighting the need for direct involvement or formalized supervision by specialist HTC physicians. Conclusions This guidance provides a reference pathway to be implemented in the different healthcare organizations, especially for the challenging emergency management in this setting.

Published
2020

2. The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany

Author

Berntorp, E, Dargaud, Y, Hart, D, Lobet, S, Mancuso, M, D'Oiron, R, Perry, D, Pollard, D, van den Berg, M, Blatny, J, Chambost, H, Doria, A, Holme, P, Kaczmarek, R, Mantovani, L, Mclaughlin, P, Nanayakkara, L, Petrini, P, Sannie, T, Laane, E, Maia, R, Dettoraki, A, Farrell, A, Halimeh, S, Raza, S, Taylor, S, Berntorp E., Dargaud Y., Hart D., Lobet S., Mancuso M. E., d'Oiron R., Perry D., Pollard D., van den Berg M., Blatny J., Chambost H., Doria A. S., Holme P. A., Kaczmarek R., Mantovani L., McLaughlin P., Nanayakkara L., Petrini P., Sannie T., Laane E., Maia R., Dettoraki A., Farrell A., Halimeh S., Raza S., Taylor S., Berntorp, E, Dargaud, Y, Hart, D, Lobet, S, Mancuso, M, D'Oiron, R, Perry, D, Pollard, D, van den Berg, M, Blatny, J, Chambost, H, Doria, A, Holme, P, Kaczmarek, R, Mantovani, L, Mclaughlin, P, Nanayakkara, L, Petrini, P, Sannie, T, Laane, E, Maia, R, Dettoraki, A, Farrell, A, Halimeh, S, Raza, S, Taylor, S, Berntorp E., Dargaud Y., Hart D., Lobet S., Mancuso M. E., d'Oiron R., Perry D., Pollard D., van den Berg M., Blatny J., Chambost H., Doria A. S., Holme P. A., Kaczmarek R., Mantovani L., McLaughlin P., Nanayakkara L., Petrini P., Sannie T., Laane E., Maia R., Dettoraki A., Farrell A., Halimeh S., Raza S., and Taylor S.

Abstract

The first Team Haemophilia Education (THE) Meeting was held on 7–8 May 2015 in Amsterdam, The Netherlands. It aimed to promote the optimal care of patients with haemophilia through education of the multidisciplinary treatment team. This was achieved by reviewing the latest developments in haemophilia management, considering how these can be implemented in the clinic to improve patient care and providing a platform for networking and debate for all haemophilia treatment team members. The second THE Meeting was held on 19–20 May in Frankfurt, Germany, and participants included doctors, nurses, physiotherapists, patient representatives and data management staff from 20 different countries. Topics covered the role of the multidisciplinary team in delivering the best haemophilia care, challenges in the management of haemophilia across Europe, available clotting factor treatments, future treatments and the use of genetics in advising carriers of haemophilia. This report is a summary of the key developments in haemophilia care presented by various investigators and healthcare professionals at THE Meeting 2016.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results